Insulin action and insulin resistance: Diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system

American Journal of Medicine

Volumn 105, Issue 4, 1998, Pages 331-345

  Hunter, Steven J ^a   Garvey, W Timothy ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; INSULIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE;

DIABETES MELLITUS; EXOCYTOSIS; GENE MUTATION; GLUCOSE TRANSPORT; HORMONE ACTION; HYPERANDROGENISM; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

BIOLOGICAL TRANSPORT, ACTIVE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; RECEPTOR, INSULIN; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 0032191856     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00300-3     Document Type: Review

References (100)

1. 1. Himsworth HP. Diabetes mellitus. Its differentiation into insulin-sensitive and insulin-insensitive types. Lancet. 1936;2:935-936.
2. 2. Shipp JC, Cunningham RW, Russell RD, Marble A. Insulin resistance. Clinical features, natural course and effects of adrenal steroid treatment. Medicine. 1965;4:165-186.
3. 3. Yalow RS, Berson SA. Plasma insulin concentrations in nondiabetic and early diabetic subjects. Determinations by a new sensitive immunoassay technique. Diabetes. 1960;9:254-260.
4. 4. Kahn CR. Insulin resistance, insulin sensitivity and insulin unresponsiveness. A necessary distinction. Metabolism. 1978;27:1893-1902.
5. 5. Tager H, Given B, Baldwin D, et al. A structurally abnormal insulin causing human diabetes. Nature. 1979;281:122-125.
6. 6. Gabbay KH, De Luca K, Fisher JN, et al. Familial hyperproinsulinaemia. An autosomal dominant defect. NEJM. 1976;294:911-915.
7. 7. Davidson JK, DeBra DW. Immunologic insulin resistance. Diabetes. 1978;27:307-318.
8. 8. Paulsen EP, Courtney JW, Duckworth WC. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes. 1979;28:640-645.
9. 9. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest. 1990;85: 1844-1853.
10. 10. Lillioja S, Young AA, Culter CL, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest. 1987;80:415-425.
11. 11. Eisenberg BR. Quantitative ultrastructure of mammalian skeletal muscle. In: Peachey LD, ed. Handbook of physiology: skeletal muscle. Baltimore: Williams & Wilkins; 1983:73-111.
12. 12. Yang YJ, Hope ID, Ader M, Bergman RN. Insulin transport across capillaries is rate limiting for insulin action in dogs. J Clin Invest. 1989;84:1626-1628.
13. 13. Jacobs S, Cuatrecasas P. Insulin receptor. Structure and function. Endocr Rev. 1981;2:251-263.
14. 14. Zhang B, Roth RA. Binding properties of chimeric insulin receptors containing the cysteine-rich domain of either the insulin-like growth factor 1 receptor or the insulin receptor related receptor. Biochemistry. 1991;30:5113-5117.
15. 15. Kasuga M, Karlsson FA, Kahn CR. Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. Science. 1982;215:185-187.
16. 16. Roth RA, Cassell MP. Insulin receptor. Evidence that it is a protein kinase. Science. 1983;219:299-301.
17. 17. Frattali AL, Treadway JL, Pessin JE. Transmembrane signaling by the human insulin receptor kinase. Relationship between intramolecular beta subunit trans-and cis autophosphorylation and substrate kinase activation. J Biol Chem. 1992;267:19521-19528.
18. 18. Rosen OM. Structure and function of insulin receptors. Diabetes. 1989;38:1508-1511.
19. 19. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev. 1995;16:117-142.
20. 20. Danielson AG, Liu F, Hosomi Y, Shii K, Roth RA. Activation of protein kinase C alpha inhibits signaling by members of the insulin receptor family. J Biol Chem. 1995;270:21600-21605.
21. 21. Sun XJ, Rothenberg P, Kahn CR, et al. The structure of the insulin receptor substrate 1RS-1 defines a unique signal transduction protein. Nature. 1991;352:73-77.
22. 22. Collett MS, Erikson RL. Protein kinase activity associated with the avian sarcoma virus src gene product. Proc Natl Acad Sci USA. 1978;75:2021-2024.
23. 23. Sun XJ, Wang LM, Zhang Y, et al. Role of IRS-2 in insulin and cytokine signaling. Nature. 1995;377:173-177.
24. 24. Lavan BE, Lane WS, Lienhard GE. The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J Biol Chem. 1997;272:11439-11443.
25. 25. Lavan BE, Fantin VR, Chang ET, et al. A novel 160-kDa phosphotyrosine protein in insulin-treated embyronic kidney cells is a new member of the insulin receptor substrate family. J Biol Chem. 1997;272:21403-21407.
26. 26. Pelicci GL, Lanfrancone L, Grignani F, et al. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell. 1992;70:93-104.
27. 27. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 1998;391:900-904.
28. 28. Hausdorff SF, Frangioni JV, Birnbaum MJ. Role of p21ras in insulin-stimulated glucose transport in 3T3-L1 adipocytes. J Biol Chem. 1994;269:21391-21394.
29. 29. Stralfors P. Insulin second messengers. BioEssays. 1997;19:327-335.
30. 30. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active akt ser/thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem. 1996;271:31372-31378.
31. 31. Calera MR, Martinez C, Liu H, et al. Insulin increases the association of akt-2 with Glut4-containing vesicles. J Biol Chem. 1998; 273:7201-7204.
32. 32. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril. 1988;50: 197-212.
33. 33. Cruz PD, Hud JA. Excess insulin binding to insulin-like growth factor receptors. Proposed mechanism for acanthosis nigricans. J Invest Dermatol. 1992;98:82S-85S.
34. 34. Taylor SI, Wertheimer E, Hone J, et al. Mutations in the insulin receptor gene in patients with genetic syndromes of extreme insulin resistance. In: Draznin B, LeRoith D, eds. Molecular Biology of Diabetes, vol 2. Philadelphia: Humana Press; 1994:1-23.
35. 35. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin receptor disorders in man. NEJM. 1976;294:739-745.
36. 36. O'Rahilly S, Moller DE. Mutant insulin receptors in syndromes of insulin resistance. Clin Endocrinol. 1992;36:121-132.
37. 37. Mechanick J, Dunaif A. Masculinization: a clinical approach to the diagnosis and treatment of hyperandrogenic women. In: Mazzaferi E, ed. Advances in Endocrinology and Metabolism, vol. 1. Chicago: Mosley-Year Book; 1990:129-173.
38. 38. Dunaif A, Segal K, Shelley D, et al. Profound peripheral insulin resistance independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-1174.
39. 39. Poretsky L, Kalin MF. The gonadotropic function of insulin. Endoer Rev. 1987;8:132-141.
40. 40. Stuart CA, Prince MJ, Peters MJ, Meyer WJ. Hyperinsulinemia and hyperandrogenemia. Androgen response to insulin infusion. Obstet Gynecol. 1987;69:921-925.
41. 41. Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome. A common endocrinopathy was distinct pathophysiologic features. Am J Obstet Gynecol. 1983;147: 90-101.
42. 42. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 1995;16:322-353.
43. 43. Dunaif A, Green G, Futterweit W, Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1990;70:699-704.
44. 44. Dunaif A. Insulin resistance and ovarian dysfunction. In: Moler DE, ed. Insulin Resistance. Chichester: Wiley; 1993:301-325.
45. 45. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995;96:801-810.
46. 46. Kanety H, Feinstein R, Papa MZ, et al. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem. 1995;270: 23780-23784.
47. 47. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science. 1996;271:665-668.
48. 48. Paz K, Hemi R, LeRoith D, et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem. 1997;272:29911-29918.
49. 49. Ciaraldi TP, Morales AJ, Hickman MG, et al. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab. 1997;82:1421-1425.
50. 50. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992;36:105-111.
51. 51. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. NEJM. 1996;335: 617-623.
52. 52. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81:3299-3306.
53. 53. Ehrmann DA, Schneider DJ, Burton ES, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;1997:2108-2116.
54. 54. Lehmann J, Moore L, Smith-Oliver T, et al. An antidiabetic thiazolidenedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR). J Biol Chem. 1995;270:12953-12956.
55. 55. Kliewer S, Lenhard J, Willson T, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor and promotes adipocyte differentiation. Cell. 1995;83:813-819.
56. 56. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest. 1997;100:1863-1869.
57. 57. Garvey WT, Birnbaum MJ. Cellular insulin action and insulin resistance. Baillieres Clin Endocrinol Metab. 1993;7:785-873.
58. 58. Bao S, Smith RM, Jarett L, Garvey WT. The effects of brefeldin A on the glucose transport system in rat adipocytes. Implications regarding the intracellular locus on insulin sensitive GLUT4. J Biol Chem. 1995;270:30199-30204.
59. 59. Rea S, James DE. Moving GLUT4. The biogenesis and trafficking of GLUT4 storage vesicles. Diabetes. 1997;46:1667-1677.
60. 60. Kandror KV, Pilch PF. Compartmentalization of protein traffic in insulin-sensitive cells. Am J Physiol. 1996;271:E1-E14.
61. 61. Rice JE, Livingstone C, Gould GW. Trafficking, targeting and translocation of the insulin-responsive glucose transporter, GLUT4, in adipocytes. Biochem Soc Trans. 1996;24:540-546.
62. 62. Holman GD, Kasuga M. From receptor to transporter. Insulin signalling to glucose transport. Diabetologia. 1997;40:910-1003.
63. 63. Malide D, Dwer NK, Blanchette-Mackie EJ, Cushman SW. Immunocytochemical evidence that GLUT4 resides in a specialized translocation post-endosomal VAMP-2 positive compartment in rat adipose cells in the absence of insulin. J Histochem Cytochem. 1997;45:1083-1096.
64. 64. Aledo JC, Lavoie L, Volchuk A, et al. Identification and characterization of two distinct intracellular GLUT4 pools in rat skeletal muscle. Evidence for an endosomal and an insulin-sensitive GLUT4 compartment. Biochem J. 1997;325:727-732.
65. 65. Czech MP. Molecular actions of insulin on glucose transport. Annual Rev Nutr. 1995;15:441-471.
66. 66. Kandror KV, Pilch PF. gp 160, A tissue specific marker for insulin-activated glucose transport. Proc Natl Acad Sci USA. 1994;91: 8017-8021.
67. 67. Sollner TH, Rothman JE. Molecular machinery mediating vesicle budding, docking, and fusion. Cell Struct Funct. 1996;21:407-412.
68. 68. Pevsner J, Hsu S-C, Braun JEA, et al. Specificity and regulation of a synaptic vesicle docking complex. Neuron. 1994;13:353-361.
69. 69. Novick P, Zerial M. The diversity of rab proteins in vesicle transport. Curr Opin Cell Biol. 1997;9:496-504.
70. 70. Warram JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Int Med. 1990; 113:909-915.
71. 71. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. NEJM. 1993; 329:1988-1992.
72. 72. Hattersley AT. Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet Med. 1998; 15:15-24.
73. 73. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75:473-486.
74. 74. Stout RW. Hyperinsulinemia, dyslipidemia and atherosclerosis. In: Moller DE, ed. Insulin Resistance. Chichester: Wiley; 1993:355-384.
75. 75. Stern MP. Diabetes and cardiovascular disease. "The common soil hypothesis." Diabetes. 1995;44:369-374.
76. 76. Barker DJP, Hales CN, Fall CHD, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X). Relation to reduced fetal growth. Diabetologia. 1993;36:62-67.
77. 77. DeFronzo RA, Bonnadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15:318-368.
78. 78. Modan M, Halkin H, Almog S, et al. Hyperinsulinaemia. A link between hypertension, obesity and glucose intolerance. J Clin Invest. 1985;75:809-817.
79. 79. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. NEJM. 1987;317:350-357.
80. 80. Capaldo B, Lembo G, Napoli R, et al. Skeletal muscle is a primary site of insulin resistance in essential hypertension. Metabolism. 1991;40:1320-1322.
81. 81. Shamiss A, Carroll J, Rosenthal T. Insulin resistance in secondary hypertension. Am J Hypertens. 1992;5:26-28.
82. 82. Bogardus C, Lillioja S, Stone K, Mott D. Correlation between muscle glycogen synthase activity and in vivo insulin action in man. J Clin Invest. 1984;73:1185-1190.
83. 83. Bonadonna RC, Del Prato S, Sacomani MP, et al. Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. J Clin Invest. 1993;92:486-494.
84. 84. Kelley DE, Minton MA, Watkins SC, et al. The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest. 1996; 97:2705-2713.
85. 85. Katz A, Nyomba BL, Bogardus C. No accumulation of glucose in human skeletal muscle during euglycemic hyperinsulinemia. Am J Physiol 1988;255:E942-E945.
86. 13C nuclear magnetic resonance spectroscopy. NEJM. 1990;322:223-228.
87. 87. Dohm GL, Tapscott EB, Pories WJ, et al. An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J Clin Invest. 1988;82:486-494.
88. 88. Garvey WT, Maianu L, Huecksteadt TP, et al. Pretranslational suppression of a glucose transporter protein causes cellular insulin resistance in non-insulin-dependent diabetes mellitus and obesity. J Clin Invest. 1991;87:1072-1081.
89. 89. Freidenberg GR, Suter SL, Henry RR, et al. In vivo stimulation of the insulin receptor kinase in human skeletal muscle. Correlation with insulin-stimulated glucose disposal during euglycemic clamp studies. J Clin Invest. 1991;87:2222-2229.
90. 90. Goodyear LJ, Giorgino F, Sherman LA, et al. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest. 1995;95: 2195-2204.
91. 91. Freidenberg GR, Reichart D, Henry RR, Olefsky JM. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin dependent diabetes mellitus. J Clin Invest. 1988;82:1398-1406.
92. 92. Garvey WT, Maianu L, Zhu J-H, et al. Multiple defects in the adipocyte glucose transport system cause cellular insulin resistance in gestational diabetes. Heterogeneity in the number and a novel abnormality in subcellular localization of GLUT4 glucose transporters. Diabetes. 1993;42:1773-1785.
93. 93. Garvey WT, Maianu L, Brechtel G, et al. Muscle GLUT4 expression is a familial trait and determines insulin sensitivity in humans independent of obesity. Diabetes. 1994;43(suppl 1):69A.
94. 94. Hardin D, Azzarelli B, Edwards J, et al. Mechanisms of enhanced insulin sensitivity in endurance-trained athletes. J Clin Endocrinol Metab. 1995;80:2437-2446.
95. 95. Garvey WT, Maianu L, Hancock JA, et al. Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes. 1992;41:465-475.
96. 96. Garvey WT, Maianu L, Zhu J-H, et al. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest. 1998;101:2377-2386.
97. 97. Maianu L, Keller S, Garvey WT. Fat and muscle express a common abnormality in translocation/trafficking of GLUT4/vp165 containing vesicles in NIDDM. Diabetes. 1996;45(suppl. 2):157A.
98. 98. Garvey WT, Olefsky JM, Matthaei S, Marshall S. Glucose and insulin coregulate the glucose transport system in primary cultured adipocytes. A new mechanism of insulin resistance. J Biol Chem. 1987;262:189-197.
99. 99. Kin PA, Horton ED, Hirshman MF, Horton ES. Insulin resistance in obese Zucker rat (fa/fa) skeletal muscle is associated with a failure of glucose transporter translocation. J Clin Invest. 1992;90: 1568-1575.
100. 100. Baron AD, Zhu J-S, Zhu J-H, et al. Glucosamine induces insulin resistance in vivo by affecting GLUT4 translocation in skeletal muscle. Implications for glucose toxicity. J Clin Invest. 1995;96: 2792-2801.